Arrhythmia is one of the common cardiovascular diseases in China, among whichThe most typical atrial fibrillation, Research has foundThe standardized prevalence of atrial fibrillation in Chinese adults is 1.6%, with nearly 20 million patients with atrial fibrillation., with significant regional differences, there is an urgent need to strengthen the construction of a standardized management system for single disease type of atrial fibrillation.3。Data show that the incidence of stroke in patients with atrial fibrillation is 3-5 times higher than that in people without atrial fibrillation; meanwhile, 20%-30% of patients with atrial fibrillation will experience heart failure symptoms.4. Compared with traditional drug treatments,Radiofrequency ablation therapy can effectively improve patient survival rates and reduce the risk of recurrence.。“The goal of atrial fibrillation treatment is to help patients restore and maintain sinus rhythm in the long term, and prevent recurrence., "Director of the Arrhythmia Center at Fuwai Hospital, Chinese Academy of Medical SciencesProfessor YAO Yan"Safety and effective rhythm control is the ideal strategy for atrial fibrillation treatment. This yearAbbott's Two New Products Approved for Marketing in China, providing doctors with a comprehensive innovative solution, which will push electrophysiological diagnosis and treatment technology in China to a higher level, allowing more patients to benefit from it."
▲Professor YAO Yan, Director of the Arrhythmia Center at Fuwai Hospital, Chinese Academy of Medical Sciences
EnSite™ X EP System 3D Cardiac Electrophysiology Mapping System, withHigh-resolution 3D models, precise catheter navigation dual-mode options, and accurate potential algorithmsCharacterized by, achieving high-precision diagnostic and treatment decision support5This product has recently completed its first batch of surgeries, bringing precise and efficient atrial fibrillation treatment experience to Chinese physicians and patients.TactiFlex™ Ablation Catheter, Sensor Enabled™ Single-Use Magnetic and Electric Positioning Pressure Monitoring Radiofrequency Ablation Catheter is Abbott's new generation contact pressure catheter with a flexible tip.Flexible, dragon-scale-like laser-etched tip with 2 times the stability of traditional catheters6; In addition, the catheter features a light-sensitive pressure design and magnetic-electric dual positioning technology, ensuring precise contact pressure while providing a safer, more stable, and efficient ablation experience through directional irrigation and tip temperature monitoring.Research data shows that the combined use of the two products can reduce the total time of the ablation procedure by 70%.7。
▲EnSite™ X EP System 3D Cardiac Electrophysiology Mapping System
▲TactiFlex™ Ablation Catheter, Sensor Enabled™
Single-Use Magnetic and Electrical Positioning Pressure Monitoring Radiofrequency Ablation CatheterDirector of the Cardiology Center, Beijing Anzhen Hospital, Capital Medical UniversityProfessor Changsheng MaSaid: "In radiofrequency ablation surgery,Accurate and efficient localization of the lesion and safe, stable catheter ablation are key to the success of the surgery.. With the continuous implementation of innovative technologies, surgeons are able to obtain more realistic and accurate information, thereby optimizing treatment plans and operational experiences. This not only significantly reduces the risk of postoperative recurrence but also greatly improves the quality of life for patients."
▲Beijing Anzhen Hospital, Capital Medical University
Professor Ma Changsheng, Director of the Cardiology CenterGeneral Manager of Abbott Electrophysiology Business in ChinaLiu BeiStated: "As a leader in the cardiac electrophysiology diagnosis and treatment industry, Abbott offers a comprehensive range of electrophysiology solutions to address the serious challenges posed by arrhythmias worldwide. With the official launch of our full electrophysiology solution in China, we hope...Empowering Arrhythmia Diagnosis and Treatment in China with High-Quality Innovative Medical Devices to Benefit More Patients"In the future, we will continue to collaborate with multiple parties to promote physician training and development in the electrophysiology industry, safeguarding every beating heart."
After more than 30 years of deep cultivation in China, Abbott has successively launchedElectrophysiology product portfolio, including diagnostic catheters, mapping systems, and ablation catheters, comprehensively advancing the diagnosis and treatment of arrhythmias towards greater safety, precision, and efficiency. In the future, Abbott Electrophysiology will continue to focus on technological innovation, further promoting new developments in areas such as atrial fibrillation ablation treatment in China. It will support physicians in providing more comprehensive and flexible diagnostic and treatment options for patients with arrhythmias, shaping the future of healthcare.
1 Registration Certificate No.: China Medical Device Registration Approval 20243070386
2 Registration Certificate No.: China Medical Device Registration Import 20243010568
3 "Prevalence and Risk of Atrial Fibrillation in China: A National Cross-Sectional Epidemiological Study" ("Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study") https://news.whu.edu.cn/info/1015/67097.htm
4 Kotecha D, Lam CS, Van Veldhuisen DJ, et al. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins[J]. J Am Coll Cardiol, 2016, 68(20): 2217 2228. DOI: 10.1016/j.jacc.2016.08.048.
5 Abbott. Data on File. Document #90471779.
6 Ambrosius Nick, Fish Jeffrey, Tranter John, Abbott Laboratories. Flexible, kerfed ablation catheter tip provides superior stability in a bench model [abstract]. In: APHRS 2018: Abstract Book; 2018, October 17-18; Taipei, Taiwan. Abstract nr 1170.
7 Ptaszek LM et al. Safe and effective delivery of high-power, short-duration radiofrequency ablation lesions with a novel, flexible-tip radiofrequency ablation catheter [abstract]. In: Heart Rhythm 2021: July 28-31, Boston. Heart Rhythm Volume 18, Issue 9, Supplement. Elsevier; 2021. Abstract nr B-PO02-109.
